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The expression of podoplanin is
associated with poor outcome in
cutaneous squamous cell carcinoma
Background: Cutaneous squamous cell carcinoma (CSCC) is the
second most frequent cancer in humans and can be both locally
invasive and metastatic at distant sites. While research efforts have
been made to predict poor outcome of CSCC, there is a lack of
knowledge regarding molecular markers. Podoplanin has been
associated with poor outcome in several types of cancer including
CSCC, but this is controversial and only a few studies have
evaluated the prognostic implications of podoplanin in the
development of this tumor.
Methods: We evaluated podoplanin expression in a series of 94
CSCCs, and searched for associations between podoplanin
expression and histopathological characteristics and with events
of poor clinical evolution of the disease.
Results: Podoplanin expression was observed in 48.9% of the
cases and the expression was considered moderate to intense in
19 of the cases. Moderate/intense podoplanin was associated with
infiltrative growth pattern, desmoplasia, lymphovascular invasion,
higher risk of nodal progression (NP) and short disease-free
survival, specifically with a short latency to NP.
Conclusions: This article provides evidence supporting the
implication of podoplanin expression as a marker of bad
prognosis of CSCC.
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Cutaneous squamous cell carcinoma (CSCC)
represents the most common form of skin cancer
after basal cell carcinoma and can be both locally
invasive and metastatic at distant sites.1,2 Around
700,000 CSCCs new cases are diagnosed annually
in the United States, comprising a proportion of
20% of all non-melanoma skin cancer (NMSC).3
While most CSCC cases have an excellent prog-
nosis, there is a subset with a high risk of
developing local recurrence (LR) and metas-
tases. The risk of nodal metastases ranges from
3.7 to 5.2%, and disease-specific death ranges
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from 1.5 to 2.1% in CSCC patients.4 Given the
high frequency of CSCC and its increasing inci-
dence, the clinical implications of CSCC are of
paramount importance and its associated costs
are high.5 Several clinical and histopathologi-
cal risk factors have been used to predict bad
clinical evolution in patients diagnosed with
CSCC,6–8 but there is an evident lack of knowl-
edge concerning molecular and protein mark-
ers that could be used to predict outcome of
this disease.
Podoplanin is essential in lymphatic vessel
development9 and also participates in tumor
invasion and progression.10 It was originally
identified as a cell-surface antigen expressed
in mouse epidermal keratinocytes during skin
remodeling and carcinogenesis.11 Podoplanin
expression was also linked to epidermal to mes-
enchymal transition (EMT), cell migration12
and to an alternative pathway for tumor cell
invasion in the absence of EMT.13 Podoplanin
is also involved in the actin remodeling of
the cytoskeleton of tumor cells and may
promote tumor cell invasion by increasing
cell motility.13
Podoplanin expression has been associated
with poor outcome in some types of cancer.
Podoplanin is upregulated in several human can-
cers such as squamous cell carcinoma (SCC) of
the oral cavity,14–16 skin adnexal carcinomas,17
esophageal SCC18 and SCC of the penis.19 Some
papers have showed that podoplanin expression
is associated with a higher risk of nodal metastasis
in CSCC,20,21 but there is still debate regarding its
real relevance as a prognostic marker. This study
provides further evidence regarding the prog-
nostic implications of podoplanin expression in
primary CSCCs, and highlights its relevance in
predicting disease-free survival.
Patients, material and methods
Clinical, epidemiological and histopathological features
of CSCCs
We evaluated a series of 94 CSCCs. We selected
some tumors in a prospective way, and other
tumors were retrospectively collected in order
to obtain a higher proportion of CSCC with
poor outcome and high risk features. Patients
were included following the Helsinki Decla-
ration and the requirements set out by the
Local Bioethical Committee of the University
Hospital of Salamanca. We considered different
tumor and epidemiological variables of CSCCs,
clinical-epidemiological and histopathologi-
cal features and their distribution along the
cohort are described on Table S1, Supporting
Information. Specifically, we considered the
following values:
Clinical and epidemiological variables
(a) Age and sex of patients; (b) Previous his-
tory of dermatological diseases, including actinic
keratoses, NMSC and CSCC; (c) Tumor location
was categorized as: (i) head and neck high-risk
areas (ear, lower lip, temple, nose, eyelid and
preauricular region); (ii) head and neck low-risk
areas (rest of head and neck locations) and (iii)
trunk and extremities; (d) Presence of immuno-
suppression; (e) History of chronic sun exposure
and (f) American Joint Committee on Cancer
(AJCC) stage at diagnosis and at the end of the
follow-up period.
Histopathological variables
(a) Tumor size and thickness (in millime-
ters), both measured using the OV100 software
(Olympus™, Tokyo, Japan); (b) grade of differ-
entiation, which was classified as good, moderate
or poor, according to previous reports22; (c)
growth pattern was classified as expansive, infil-
trative or mixed. Infiltrative growth pattern was
considered when the tumor exhibited small
nests, rows of cells and/or isolated tumor cells in
the periphery of the tumor, an expansive pattern
was assigned when the tumor exhibited a com-
pact growth, with no-disaggregated cells in the
front of invasion and mixed growth pattern was
assigned when the tumor displayed an expan-
sive growth pattern and tended to infiltrate in
any part of the front of invasion; (d) perineu-
ral invasion; (e) lymphovascular invasion; (f)
desmoplasia was defined by the thickening of
collagen bundles around and inside the tumor
involving at least 30% of the stroma6; (g) solar
elastosis and (h) actinic keratosis associated with
tumor (in flanking epithelium).
Time to events of poor clinical evolution during follow
up (in months)
(a) LR; (b) NP; (c) distant progression, which
was considered when the tumor developed
metastases in solid organs during the follow-up
period; (d) death from CSCC and (e) any of the
aforementioned events.23
Tissue microarray and immunohistochemistry
Tissue samples, formalin-fixed paraffin-
embedded, were used to prepare tissue microar-
rays using a tissue arrayer device (Beecher
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Instruments, Sun Prairie, WI, USA). Three
1-mm-diameter cylinders from each tumor were
included to ensure reproducibility and homo-
geneous staining of the slides. Three different
areas of each tumor were selected to reproduce
the heterogeneity of the samples.
Immunohistochemical studies were per-
formed using the AutostainerLink 48 (Dako,
Santa Clara, CA, USA). Antibody anti-human
against podoplanin, clone D2-40 (Dako, Santa
Clara, CA, USA) of mouse origin, was used
(prediluted). The detection system used the kit
EnVision/HRP Flex Plus (Dako®, Santa Clara,
CA, USA) and positive controls were included
in each slide.
A semiquantitative analysis of podoplanin
expression level was performed by three inde-
pendent observers (JC, CR-C and EC-A). The
intensity of podoplanin expression and the
percentage of positive cells in each tumor were
calculated as carried out by other groups.20,21
Podoplanin intensity of expression was calcu-
lated as 0: null; 1: weak; 2: moderate and 3:
intense; and the percentage of positive cells was
considered as 0: null (<25% of stained cells); 1:
weak (25–50%); 2: moderate (50–75%) and 3:
intense (>75%). A mean with podoplanin inten-
sity of expression and podoplanin percentage
of stained cells were calculated to determine
the amount of podoplanin expression in each
tumor, as previously described.21 Podoplanin
expression was later transformed into a dichoto-
mous variable with category 0 (absent and weak
podoplanin expression: −/+) and category 1
(moderate and intense podoplanin expression:
++/+++). We only considered podoplanin
expression in epithelial tumor cells in order to
classify CSCC.20,21
Lymphovascular invasion was evaluated and
considered positive when tumor cells (either iso-
lated or organized in clusters) were surrounded
by podoplanin-positive lymphatic vessels.
Statistical analysis
Statistical analysis was performed using the
IBM SPSS v.21 software. Categorical vari-
ables were compared using the Chi-square
or the Fisher exact test when appropriate.
The Kolmogorov-Smirnov test showed that
continuous variables did not follow a normal
distribution. When two independent samples
were analyzed, the Mann-Whitney U test was
used. To evaluate which variables predicted
events of poor clinical evolution, we developed
logistic regression models and used the Wald
test. We considered p values <0.05 as significant,
and confidence intervals at 95%.
Results
Podoplanin expression in CSCC
To determine the utility of podoplanin expres-
sion as a marker of prognosis in CSCC, we eval-
uated podoplanin expression by immunohisto-
chemistry in a cohort of 94 CSCCs (Fig. 1 and
Table 1). A total of 48 tumors (51.1%) displayed
no expression, 27 tumors (28.8%) showed weak
expression, 15 tumors (16%) showed moder-
ate expression and 4 tumors (4.3%) displayed
intense expression of podoplanin (Table 1).
Podoplanin expression was located mainly in
lymphatic vessels, but in some cases also in
tumor cells in which podoplanin exhibited a
cytoplasmic staining, sometimes with cell mem-
brane enhancement. Podoplanin also tended to
be expressed along the front of invasion of the
tumors, especially in those cases with an infiltra-
tive growth pattern (Fig. 1).
Podoplanin expression is associated with histopathological
tumor traits and with events of poor outcome in CSCC
Following on, we studied the existence of
associations between podoplanin expression
and histopathological tumor traits. Mod-
erate/intense podoplanin expression was
associated with the presence of desmoplasia
(p= 0.031), with an infiltrative growth pattern
(p= 0.013) and with the presence of lympho-
vascular invasion (p= 0.011). Moderate/intense
podoplanin expression was also found more
frequently in those tumors that exhibited
ulceration (p= 0.002) and a poor grade of dif-
ferentiation with a statistical trend (p= 0.057)
although, expression was not associated with
perineural invasion (Fig. 2 and Table 1).
Moderate/intense podoplanin expression
was not associated with AJCC stage at diagnosis
but it correlated with AJCC stage at the end
of follow up. Thus, podoplanin expression was
more common in tumors at the higher stages
(p= 0.032) and with progression of the AJCC
stage (p= 0.022). More interestingly, mod-
erate/intense podoplanin expression in the
primary tumor correlated with higher risk of
nodal metastasis during follow up (p= 0.022)
(Table 1), which was particularly evident for
tumors at stage 2 (p= 0.01) (Fig. 2C).
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Fig. 1. Evaluation of podoplanin expression by immunohistochemistry in cutaneous squamous cell carcinoma (CSCC).
A) Podoplanin expression in lymphatic vessels: (a1) Hematoxilin and eosin (H&E) staining of the CSCC zone with
lymphatic vessels (blue arrows) (×400) and (a2) increased magnification (×400) showing more detail. B) Podoplanin expres-
sion in an infiltrative CSCC: (b1) H&E of tumor cells (×200); (b2) podoplanin expression in tumor cells showing cyto-
plasmic podoplanin staining (×200) and (b3) (×400). C) Podoplanin expression along the front of invasion in CSCC: (c1)
H&E staining in an infiltrative CSCC (×200). Podoplanin expression along the front of invasion of the tumor (c2) (×200)
and (c3) (×400).
Podoplanin predicts short disease-free relapse in CSCC
Later, we assessed whether podoplanin expres-
sion could serve as a biomarker of time to
disease relapse in CSCC. The median follow-up
period of all the patients was 70 months (range
36–90 months). The latency to any event of poor
clinical evolution was shorter for those patients
with tumors that expressed podoplanin at mod-
erate/intense levels (p= 0.031) (Fig. 3A). Thus,
the median length of time to develop adverse
clinical events was 4.5 months [interquartile
range (IQR) 6.5] for those patients with tumors
that expressed podoplanin at moderate/intense
levels, whereas it was 11 months (IQR 21) for
those patients with tumors with absent/weak
podoplanin expression (Table 1).
Also, moderate/intense podoplanin expres-
sion was associated with a shorter latency to develop
lymph nodal metastasis (p= 0.008) (Fig. 3B).
Thus, the median length of time to NP was
5 months (IQR 4.88) for those tumors with
moderate/intense podoplanin expression, and
13 months (IQR 18) for those with absent/weak
podoplanin expression (Table 1).
We carried out a logistic regression model to
evaluate the plausibility of podoplanin expres-
sion acting as an independent variable able to
predict CSCC prognosis. We only found it to be
associated with the lymph node metastasis model
(Table 2). In addition to podoplanin expression,
we introduced tumor traits related to CSCC
prognosis and presumed to be predictable
variables according to the literature.6,24,25
These included desmoplasia, growth pattern,
perineural infiltration, tumor thickness, tumor
size and degree of differentiation, some of which
have been associated with poor prognosis by uni-
variate analysis in our cohort (Tables S2 and S3).
Only perineural infiltration and podoplanin
expression were the variables associated with
short disease-free time to relapse in our cohort.
AJCC stage did not correlate with differences in
the time to events and NP.
Discussion
In this study, we showed that moderate/intense
podoplanin expression was associated with
histopathological features of poor outcome in
CSCC, with NP and a short latency to events of
poor clinical evolution generally considered,
and in particular, with nodal metastasis.26
We found podoplanin expression in lymphatic
vessels, and in tumor cells where, in some cases,
it exhibited cytoplasmic staining. The specific
expression of podoplanin in lymphatic endothe-
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Fig. 2. Podoplanin expression and histopathological tumor traits in cutaneous squamous cell carcinoma (CSCC). A)
Well-differentiated CSCCs with an expansive growth pattern of invasion: (a) H&E (×100); (b) H&E (×200); (c) absence of global
podoplanin expression in the tumor (×100); (d) note that lymphatic vessels are positively stained (×200). B) Poorly differentiated
CSCCs with infiltrative growth pattern of invasion; (e) H&E (×100); (f) H&E (×200); (g) intense podoplanin expression (×100)
and (h) (×200). Note the desmoplastic stroma in (f) and (h). C) Association of lymph node metastasis with podoplanin expression
in tumors at stage 2.
the expression pattern of podoplanin observed
in other types of SCC such as the carcinoma of
the oral cavity and the larynx.27–30 This find-
ing is in agreement with the role of podoplanin
in lymphatic vessel generation and remodeling,9
but there were some differences in the frequency
and the intensity of podoplanin expression,
being lower in CSCC.21 Indeed, we did observe
that the expression of podoplanin was absent in
more than 50% of the tumors in this cohort. As
podoplanin expression seems to be linked with
lymphatic metastases and with lymphatic tumor
spread, these differences in podoplanin expres-
sion frequency might reflect the lower nodal
metastatic risk in SCC of cutaneous origin.21 In
addition, we observed an association between
podoplanin expression in the primary tumor
and the presence of lymphovascular invasion,
which suggests that podoplanin is associated with
lymphatic tumor spread. Podoplanin also tended
to be expressed along the front of invasion of
tumors, especially in those cases that exhibited
an infiltrative growth pattern, and its expression
has been associated with an infiltrative growth
pattern and desmoplasia in CSCC.20
Podoplanin has been previously associated
with nodal metastasis20,21,31 and with short
survival rates in CSCC.32 Thus, podoplanin
148
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Table 1. Associations between podoplanin expression and different clinical and histopathological CSCC variables
Podoplanin expression
CSCC features Absent/weak Moderate/intense p Value
Desmoplasia Yes 13 7 0.048***
No 62 10
Growth pattern Infiltrative 37 14 0.013***
Non infiltrative 38 3
Ulceration Yes 36 15 0.007***
No 26 1
Lymphovascular invasion Yes 2 4 0.011*
No 72 13
Degree of differentiation Good-moderate 63 12 0.057*
Poor 12 7
Nodal progression Yes 7 6 0.022*
No 68 13
AJCC stage at diagnosis I 27 5 N.S.***
II 48 14




Progression AJCC stage Yes 8 6 0.033***
No 67 13
Time to events of poor prognosis (months) (Me/IQR) 11 (21) 4.5 (6.5) 0.031**
Time to nodal progression (months) (Me/IQR) 13 (18) 5 (3.5) 0.008**
CSCC, cutaneous squamous cell carcinoma; IQR, interquartile range; Me, median; N.S. not significant.
Significant p values are in bold; Statistical trend is indicated by italics.
*Fisher exact test; **Mann-Whitney U test; ***Chi-square test was used in those cases with no specification.
seems to be a marker associated with NP in
CSCC.20,21 Here, we also found an association
between nodal metastasis and moderate/intense
podoplanin expression in CSCC. Although
podoplanin expression has been associated with
relapse in CSCC, we did not find an association
between this marker and LR in our series. Other
authors have found correlation between low
podoplanin expression and lymphatic spread as
well as with nodal metastases in uterine cervical
cancer33 and in lung cancer,34 and it seems
podoplanin may play a different role depending
on the cancer type.
The association of podoplanin expression
with latency to events of bad clinical evolution
has been poorly evaluated in CSCC. In our
study, moderate/intense podoplanin expression
was associated with a short latency to global
events and with a short latency to NP. Indeed,
podoplanin expression was the unique variable
associated with short disease-free time of to
relapse. AJCC stage at diagnosis was inadequate
to predict latency to events of bad clinical evo-
lution. Also podoplanin expression, which did
not correlate with AJCC stage at diagnosis, did
correlate with AJCC stage at the end of follow up
and with the progression of AJCC stage. Thus,
podoplanin expression could be a useful marker
to identity tumors with a high risk of progression
and could give additional prognostic infor-
mation for CSCC AJCC stage at diagnosis, in
particular for these tumors at stage 2 (Fig. 2C).
In conclusion, this paper confirms podoplanin
as a marker of poor prognosis in CSCC. We show
that podoplanin expression predicts a higher
risk for the development of nodal metastasis in
Table 2. Identification of podoplanin expression and perineural infiltration as independent variables to predict lymph node metastasis by logistic
regression
Logistic regression model Independent factors OR CI p Value
Lymph node metastasis PNI 5.75 1.540–21.467 0.009
Podoplanin (++/+++) 5.165 1.326–20.126 0.018
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Fig. 3. Differences in disease-free time to relapse associated
with podoplanin expression. A) podoplanin expression is asso-
ciated with short disease-free time of relapse in cutaneous squa-
mous cell carcinoma (CSCC). B) podoplanin expression is asso-
ciated with a short latency to lymph nodal progression in CSCC.
CSCC, as others have also described,20,27 and
is also a marker of an early appearance of a
clinical event. This article provides evidence
for the prognostic implications of podoplanin
expression, and suggests that CSCCs with mod-
erate/intense podoplanin expression should be
closely followed irrespective of other associated
risk factors. Moderate/intense expression of
podoplanin in the primary tumor, especially
in those cases with other pathological traits
of aggressiveness, could justify carrying out a
sentinel lymph node biopsy for better staging of
CSCC. While evidence is growing concerning the
prognostic implications of podoplanin expres-
sion in CSCC, further studies with larger case
series are necessary to confirm these findings.
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